Single-Time-Point Dosimetry of Lu-PSMA-617 Radionuclide Therapy with SPECT/CT.
作者信息
Burkett Brian J
出版信息
Radiol Imaging Cancer. 2023 Mar;5(2):e239006. doi: 10.1148/rycan.239006.
Abstract
摘要
相似文献
1
Single-Time-Point Dosimetry of Lu-PSMA-617 Radionuclide Therapy with SPECT/CT.
Radiol Imaging Cancer. 2023 Mar;5(2):e239006. doi: 10.1148/rycan.239006.
2
Radiation Dosimetry in Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors.
J Nucl Med. 2020 Jul;61(7):1030-1036. doi: 10.2967/jnumed.119.233411. Epub 2019 Dec 5.
3
Dosimetry of Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
J Nucl Med. 2019 Apr;60(4):517-523. doi: 10.2967/jnumed.118.219352. Epub 2018 Oct 5.
4
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919-1930. doi: 10.1007/s00259-019-04345-0. Epub 2019 May 27.
5
Dual-Time-Point Posttherapy Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome.
J Nucl Med. 2023 Sep;64(9):1431-1438. doi: 10.2967/jnumed.122.264770. Epub 2023 Jul 6.
6
Biodistribution and dosimetry for combined [Lu]Lu-PSMA-I&T/[Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging.
Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1280-1290. doi: 10.1007/s00259-022-06092-1. Epub 2023 Jan 11.
7
Evaluation of Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
J Nucl Med. 2023 Feb;64(2):221-226. doi: 10.2967/jnumed.122.264398. Epub 2022 Aug 25.
8
Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu- PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study.
Nucl Med Commun. 2024 Feb 1;45(2):115-120. doi: 10.1097/MNM.0000000000001792. Epub 2023 Nov 20.
9
First-in-human study of Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):148-158. doi: 10.1007/s00259-018-4096-y. Epub 2018 Aug 8.
10
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
Prostate. 2021 Apr;81(5):279-285. doi: 10.1002/pros.24104. Epub 2021 Jan 19.
引用本文的文献
1
Theranostics and artificial intelligence: new frontiers in personalized medicine.
Theranostics. 2024 Mar 25;14(6):2367-2378. doi: 10.7150/thno.94788. eCollection 2024.
本文引用的文献
1
Toward Single-Time-Point Image-Based Dosimetry of Lu-PSMA-617 Therapy.
J Nucl Med. 2023 May;64(5):767-774. doi: 10.2967/jnumed.122.264594. Epub 2023 Jan 19.
Zotero 插件